Is Soleno Therapeutics Stock a Good Investment?
Soleno Therapeutics Investment Advice | SLNO |
- Examine Soleno Therapeutics' financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Soleno Therapeutics' leadership team and their track record. Good management can help Soleno Therapeutics navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Biotechnology space and any emerging trends that could impact Soleno Therapeutics' business and its evolving consumer preferences.
- Compare Soleno Therapeutics' performance and market position to its competitors. Analyze how Soleno Therapeutics is positioned in terms of product offerings, innovation, and market share.
- Check if Soleno Therapeutics pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Soleno Therapeutics' stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Soleno Therapeutics stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Soleno Therapeutics is a good investment.
Sell | Buy |
Hold
Market Performance | Insignificant | Details | |
Volatility | Very steady | Details | |
Hype Condition | Stale | Details | |
Current Valuation | Overvalued | Details | |
Odds Of Distress | About Average | Details | |
Economic Sensitivity | Almost neglects market trends | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unavailable | Details |
Examine Soleno Therapeutics Stock
Researching Soleno Therapeutics' stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 97.0% of the company shares are owned by institutional investors. The company recorded a loss per share of 4.38. Soleno Therapeutics last dividend was issued on the 6th of October 2017. The entity had 1:15 split on the 26th of August 2022.
To determine if Soleno Therapeutics is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Soleno Therapeutics' research are outlined below:
| Soleno Therapeutics had very high historical volatility over the last 90 days | |
| Soleno Therapeutics has high likelihood to experience some financial distress in the next 2 years | |
| Net Loss for the year was (175.85 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Soleno Therapeutics currently holds about 24.07 M in cash with (69.1 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.97. | |
| Over 97.0% of the company shares are owned by institutional investors | |
| Latest headline from statnews.com: STAT Soleno Therapeutics life-changing drug nears approval decision |
Soleno Therapeutics uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Soleno Therapeutics. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Soleno Therapeutics' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 19th of March 2024 Upcoming Quarterly Report | View | |
| 14th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 19th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Earnings surprises can significantly impact Soleno Therapeutics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises Soleno Therapeutics' investors have experienced.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2024-03-06 | 2023-12-31 | -0.27 | -0.33 | -0.06 | 22 | ||
2022-11-09 | 2022-09-30 | -0.91 | -0.76 | 0.15 | 16 | ||
2023-05-09 | 2023-03-31 | -0.72 | -0.88 | -0.16 | 22 | ||
2025-03-04 | 2024-12-31 | -1.0771 | -1.27 | -0.1929 | 17 | ||
2024-05-09 | 2024-03-31 | -0.37 | -0.59 | -0.22 | 59 | ||
2023-03-21 | 2022-12-31 | -0.8 | -0.58 | 0.22 | 27 | ||
2018-03-16 | 2017-12-31 | -0.23 | -0.53 | -0.3 | 130 | ||
2020-11-10 | 2020-09-30 | -1.3 | -1.65 | -0.35 | 26 |
Soleno Therapeutics Target Price Consensus
Soleno target price is determined by taking all analyst projections and averaging them out. There is no one specific way to measure analysts' performance other than comparing it to past results via a very sophisticated attribution analysis. Soleno Therapeutics' target price projections below should be used in combination with other traditional price prediction techniques such as stock price forecasting, investor sentiment analysis, technical analysis, earnings estimate, and various momentum models.
| 7 | Strong Buy |
Most Soleno analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to help potential investors understand Soleno stock's fair price compared to its market value. Analysts arrive at stock ratings after researching the public financial statements of Soleno Therapeutics, talking to its executives and customers, or listening to those companies' conference calls.
Macroaxis Advice Exposure ValuationSoleno Therapeutics Target Price Projection
Soleno Therapeutics' current and average target prices are 49.18 and 74.29, respectively. The current price of Soleno Therapeutics is the price at which Soleno Therapeutics is currently trading. On the other hand, Soleno Therapeutics' target price is what analysts think the stock is worth or could sell for in the future. The more significant the discrepancy between the two prices, the more it stimulates investors to act.Current Price
Soleno Therapeutics Market Quote on 24th of March 2025
Target Price
Analyst Consensus On Soleno Therapeutics Target Price
Soleno Therapeutics Analyst Ratings
Soleno Therapeutics' analyst stock recommendations are determined by taking an average estimate of all analysts we track and classifying them as Strong Buy, Buy, Hold, Strong Sell, or Sell. Ratings generally communicate what analysts sense about Soleno Therapeutics stock, and they use a lot of effort and time to analyze it and arrive at a rating. That suggests that analyst recommendations are the outcome of an objective and thorough examination of Soleno Therapeutics' financials, market performance, and future outlook by experienced professionals. Soleno Therapeutics' historical ratings below, therefore, can serve as a valuable tool for investors.Know Soleno Therapeutics' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Soleno Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Soleno Therapeutics backward and forwards among themselves. Soleno Therapeutics' institutional investor refers to the entity that pools money to purchase Soleno Therapeutics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | State Street Corp | 2024-12-31 | 1.3 M | Vestal Point Capital Lp | 2024-12-31 | 1.1 M | Citadel Advisors Llc | 2024-12-31 | 972.4 K | Holocene Advisors, Lp | 2024-12-31 | 955.5 K | Westfield Capital Management Company, L.p. | 2024-12-31 | 881.5 K | Pictet Asset Manangement Sa | 2024-12-31 | 851.8 K | Fmr Inc | 2024-12-31 | 813 K | Wellington Management Company Llp | 2024-12-31 | 782.3 K | Sofinnova Ventures | 2024-12-31 | 757.2 K | Vivo Capital, Llc | 2024-12-31 | 6.3 M | Hhg Plc | 2024-12-31 | 5.2 M |
Soleno Therapeutics' market capitalization trends
The company currently falls under 'Mid-Cap' category with a current market capitalization of 2.25 B.Market Cap |
|
Soleno Therapeutics' profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.54) | (0.57) | |
| Return On Capital Employed | (0.28) | (0.30) | |
| Return On Assets | (0.53) | (0.56) | |
| Return On Equity | (0.72) | (0.75) |
Determining Soleno Therapeutics' profitability involves analyzing its financial statements and using various financial metrics to determine if Soleno Therapeutics is a good buy. For example, gross profit margin measures Soleno Therapeutics' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Soleno Therapeutics' profitability and make more informed investment decisions.
Evaluate Soleno Therapeutics' management efficiency
Soleno Therapeutics has return on total asset (ROA) of (0.4506) % which means that it has lost $0.4506 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.8735) %, meaning that it created substantial loss on money invested by shareholders. Soleno Therapeutics' management efficiency ratios could be used to measure how well Soleno Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of the 24th of March 2025, Return On Tangible Assets is likely to drop to -0.57. In addition to that, Return On Capital Employed is likely to drop to -0.3. At this time, Soleno Therapeutics' Total Assets are very stable compared to the past year. As of the 24th of March 2025, Non Current Assets Total is likely to grow to about 38.9 M, while Other Assets are likely to drop 0.86.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 6.10 | 6.41 | |
| Tangible Book Value Per Share | 5.93 | 6.23 | |
| Enterprise Value Over EBITDA | (12.02) | (12.62) | |
| Price Book Value Ratio | 7.37 | 7.85 | |
| Enterprise Value Multiple | (12.02) | (12.62) | |
| Price Fair Value | 7.37 | 7.85 | |
| Enterprise Value | 1.5 B | 1.6 B |
Leadership effectiveness at Soleno Therapeutics is a strong indicator of its financial stability. We analyze various metrics to provide insights into the stock's investment viability.
Beta (1.69) |
Basic technical analysis of Soleno Stock
As of the 24th of March, Soleno Therapeutics has the Risk Adjusted Performance of 0.0419, coefficient of variation of 2560.7, and Semi Deviation of 2.42. In relation to fundamental indicators, the technical analysis model makes it possible for you to check existing technical drivers of Soleno Therapeutics, as well as the relationship between them.Soleno Therapeutics' insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Soleno Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Soleno Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Soleno Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Soleno Therapeutics' Outstanding Corporate Bonds
Soleno Therapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Soleno Therapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Soleno bonds can be classified according to their maturity, which is the date when Soleno Therapeutics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| Morgan Stanley 3971 Corp BondUS61744YAL20 | View | |
| Valero Energy Partners Corp BondUS91914JAA07 | View | |
| AerCap Global Aviation Corp BondUS00773HAA59 | View |
Understand Soleno Therapeutics' technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Soleno Therapeutics' various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | 0.0419 | |||
| Market Risk Adjusted Performance | 0.0963 | |||
| Mean Deviation | 2.19 | |||
| Semi Deviation | 2.42 | |||
| Downside Deviation | 2.48 | |||
| Coefficient Of Variation | 2560.7 | |||
| Standard Deviation | 3.2 | |||
| Variance | 10.27 | |||
| Information Ratio | 0.0569 | |||
| Jensen Alpha | 0.205 | |||
| Total Risk Alpha | 0.3585 | |||
| Sortino Ratio | 0.0736 | |||
| Treynor Ratio | 0.0863 | |||
| Maximum Drawdown | 20.36 | |||
| Value At Risk | (4.78) | |||
| Potential Upside | 4.99 | |||
| Downside Variance | 6.15 | |||
| Semi Variance | 5.86 | |||
| Expected Short fall | (2.80) | |||
| Skewness | 1.41 | |||
| Kurtosis | 5.1 |
| Risk Adjusted Performance | 0.0419 | |||
| Market Risk Adjusted Performance | 0.0963 | |||
| Mean Deviation | 2.19 | |||
| Semi Deviation | 2.42 | |||
| Downside Deviation | 2.48 | |||
| Coefficient Of Variation | 2560.7 | |||
| Standard Deviation | 3.2 | |||
| Variance | 10.27 | |||
| Information Ratio | 0.0569 | |||
| Jensen Alpha | 0.205 | |||
| Total Risk Alpha | 0.3585 | |||
| Sortino Ratio | 0.0736 | |||
| Treynor Ratio | 0.0863 | |||
| Maximum Drawdown | 20.36 | |||
| Value At Risk | (4.78) | |||
| Potential Upside | 4.99 | |||
| Downside Variance | 6.15 | |||
| Semi Variance | 5.86 | |||
| Expected Short fall | (2.80) | |||
| Skewness | 1.41 | |||
| Kurtosis | 5.1 |
Consider Soleno Therapeutics' intraday indicators
Soleno Therapeutics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Soleno Therapeutics stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Soleno Therapeutics Corporate Filings
10K | 28th of February 2025 Annual report required by the U.S. Securities and Exchange Commission (SEC) of a company financial performance | ViewVerify |
8K | 27th of February 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
| 14th of February 2025 Other Reports | ViewVerify | |
F4 | 23rd of January 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
Soleno Stock media impact
Far too much social signal, news, headlines, and media speculation about Soleno Therapeutics that are available to investors today. That information is available publicly through Soleno media outlets and privately through word of mouth or via Soleno internal channels. However, regardless of the origin, that massive amount of Soleno data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Soleno Therapeutics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Soleno Therapeutics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Soleno Therapeutics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Soleno Therapeutics alpha.
Soleno Therapeutics Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Soleno Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Soleno Therapeutics Maximum Pain Price Across June 20th 2025 Option Contracts
Soleno Therapeutics' options can also be used to analyze investors' bias and current market sentiment in the context of behavioral finance. For example, Max pain usually refers to a trading concept that asserts that market manipulation can cause the market price of Soleno Therapeutics close to the expiration of its current option contract to expire worthlessly. According to most research, about 35% of options are not executed, with roughly 50% traded out before expiration. So, Max pain occurs when market makers reach a net favorable position across all options at a strike price where option holders stand to lose the most money. By contrast, option sellers may reap the most after selling more options than buying, causing them to expire worthlessly. Please continue to view the detailed analysis of Soleno Therapeutics' options.
Soleno Therapeutics Corporate Management
| Kristen MS | Senior Operations | Profile | |
| Dr MBA | Senior Development | Profile | |
| Patricia MPH | Senior Affairs | Profile | |
| PharmD MBA | Senior Affairs | Profile | |
| Meredith MBA | Chief Officer | Profile | |
| Anish MD | CEO and President | Profile |
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Soleno Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. To learn how to invest in Soleno Stock, please use our How to Invest in Soleno Therapeutics guide.You can also try the Competition Analyzer module to analyze and compare many basic indicators for a group of related or unrelated entities.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Soleno Therapeutics. If investors know Soleno will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Soleno Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Soleno Therapeutics is measured differently than its book value, which is the value of Soleno that is recorded on the company's balance sheet. Investors also form their own opinion of Soleno Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Soleno Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Soleno Therapeutics' market value can be influenced by many factors that don't directly affect Soleno Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
In summary, please note that there is a difference between Soleno Therapeutics' value and its price, as these two are different measures arrived at by various means. Investors typically determine if Soleno Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Soleno Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.